Acute panmyelosis with myelofibrosis

From WikiMD.org
(Redirected from Panmyelosis)
Jump to navigation Jump to search

Acute Panmyelosis with Myelofibrosis (APMF) is a rare subtype of acute myeloid leukemia (AML). It is characterized by the rapid progression of panmyelosis, a condition involving the abnormal proliferation of all bone marrow cells, accompanied by myelofibrosis, a serious bone marrow disorder that disrupts the body's normal production of blood cells.

Pronunciation

The term 'Acute Panmyelosis with Myelofibrosis' is pronounced as /əˈkjuːt pænˌmaɪəˈloʊsɪs wɪð ˌmaɪəloʊfaɪˈbroʊsɪs/.

Etymology

The term 'Acute Panmyelosis with Myelofibrosis' is derived from the Greek words 'akutos' (meaning 'sharp'), 'pan' (meaning 'all'), 'myelos' (meaning 'marrow'), and 'fibrosis' (from the Greek 'fibra', meaning 'fiber'). The term thus refers to a sharp or sudden condition involving all marrow cells, accompanied by fibrous tissue growth.

Related Terms

  • Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow.
  • Panmyelosis: A condition involving the abnormal proliferation of all bone marrow cells.
  • Myelofibrosis: A serious bone marrow disorder that disrupts the body's normal production of blood cells.
  • Bone Marrow: The spongy tissue inside some of your bones, such as your hip and thigh bones. It contains immature cells, called stem cells.

Symptoms

Patients with APMF may present with symptoms common to other forms of AML, such as fatigue, fever, and bleeding. However, due to the presence of myelofibrosis, they may also experience symptoms such as anemia, thrombocytopenia, and splenomegaly.

Diagnosis

Diagnosis of APMF is based on bone marrow examination, which typically shows panmyelosis and increased reticulin fibers. Additional tests such as cytogenetic analysis and molecular genetic testing may also be performed.

Treatment

Treatment for APMF is similar to that for other forms of AML and may include chemotherapy, stem cell transplantation, and supportive care.

Prognosis

The prognosis for APMF is generally poor, with a median survival time of less than a year. However, individual prognosis can vary based on factors such as age, overall health, and response to treatment.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski